PTGX · Insider Trading
Protagonist Therapeutics, Inc
Every open-market purchase and sale reported by PTGX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-02 | Asif Ali | Chief Financial Officer | MIXED | — | −$6.92M |
| 2026-09-10 | Dinesh V Ph D Patel | President and CEO | MIXED | — | −$15.54M |
| 2026-09-08 | Dinesh V Ph D Patel | President and CEO | G | −510 | — |
| 2026-08-12 | Dinesh V Ph D Patel | President and CEO | MIXED | — | −$12.73M |
| 2026-06-25 | William D. Waddill | Director | MIXED | — | −$912.60K |
| 2026-06-11 | William D. Waddill | Director | MIXED | — | −$834.48K |
| 2026-06-01 | William D. Waddill | Director | MIXED | — | −$790.56K |
| 2026-05-14 | Dinesh V Ph D Patel | President and CEO | MIXED | — | −$5.89M |
| 2026-05-12 | Dinesh V Ph D Patel | President and CEO | MIXED | — | −$5.89M |
| 2026-05-11 | Bryan Giraudo | Director | MIXED | −23,130 | −$5.68M |
| 2026-04-24 | Dinesh V Ph D Patel | President and CEO | G | −1,460 | — |
| 2026-04-21 | Asif Ali | Chief Financial Officer | Sell | −1,750 | −$184.57K |
| 2026-03-27 | Arturo Md Molina | Chief Medical Officer | MIXED | — | −$1.45M |
| 2026-03-27 | Harold E Selick | Director | MIXED | — | −$2.21M |
| 2026-03-27 | Asif Ali | Chief Financial Officer | MIXED | — | −$2.14M |
| 2026-03-25 | Dinesh V Ph D Patel | President and CEO | MIXED | −50,000 | −$5.06M |
| 2026-02-18 | Lewis T Williams | Director | MIXED | — | −$1.29M |
| 2026-02-06 | William D. Waddill | Director | MIXED | — | −$1.51M |
| 2026-01-27 | Arturo Md Molina | Chief Medical Officer | MIXED | −13,151 | −$1.82M |
| 2026-01-27 | Asif Ali | Chief Financial Officer | MIXED | −18,203 | −$3.39M |
| 2026-01-27 | Dinesh V Ph D Patel | President and CEO | MIXED | −6,000 | −$3.54M |
| 2026-01-21 | Asif Ali | Chief Financial Officer | Sell | −8,588 | −$708.34K |
| 2026-01-21 | Dinesh V Ph D Patel | President and CEO | Sell | −34,438 | −$2.84M |
| 2026-01-21 | Arturo Md Molina | Chief Medical Officer | Sell | −9,514 | −$784.71K |
| 2026-01-13 | Harold E Selick | Director | M | +14,299 | +$60.20K |
| 2026-01-06 | Sarah A O'Dowd | Director | A | +2,695 | — |
| 2026-01-06 | Bryan Giraudo | Director | A | +2,695 | — |
| 2026-01-06 | Asif Ali | Chief Financial Officer | A | +25,600 | — |
| 2026-01-06 | Dinesh V Ph D Patel | President and CEO | A | +95,400 | — |
| 2026-01-06 | William D. Waddill | Director | A | +2,695 | — |
| 2026-01-06 | Lewis T Williams | Director | A | +2,695 | — |
| 2026-01-06 | Arturo Md Molina | Chief Medical Officer | A | +25,600 | — |
| 2026-01-06 | Harold E Selick | Director | A | +2,695 | — |
| 2025-11-24 | Dinesh V Ph D Patel | President and CEO | G | −440 | — |
| 2025-11-19 | Arturo Md Molina | Chief Medical Officer | Sell | −2,712 | −$229.90K |
| 2025-10-14 | William D. Waddill | Director | MIXED | — | −$895.72K |
| 2025-09-24 | William D. Waddill | Director | Sell | −4,000 | −$257.00K |
| 2025-09-18 | Dinesh V Ph D Patel | President and CEO | G | −620 | — |
| 2025-08-29 | William D. Waddill | Director | Sell | −4,000 | −$237.00K |
| 2025-07-28 | Dinesh V Ph D Patel | President and CEO | Sell | −10,415 | −$570.53K |
| 2025-07-23 | Dinesh V Ph D Patel | President and CEO | MIXED | −27,444 | −$2.88M |
| 2025-07-18 | Dinesh V Ph D Patel | President and CEO | G | −5,000 | — |
| 2025-06-17 | Dinesh V Ph D Patel | President and CEO | G | −1,355 | — |
| 2025-06-11 | Arturo Md Molina | Chief Medical Officer | MIXED | — | −$964.60K |
| 2025-04-30 | Harold E Selick | Director | M | +10,725 | +$12.44K |
| 2025-04-23 | Asif Ali | Chief Financial Officer | Sell | −1,756 | −$80.78K |
| 2025-03-19 | William D. Waddill | Director | Sell | −4,000 | −$217.00K |
| 2025-03-14 | Arturo Md Molina | Chief Medical Officer | MIXED | — | −$953.89K |
| 2025-03-14 | Asif Ali | Chief Financial Officer | MIXED | — | −$1.09M |
| 2025-03-05 | Dinesh V Ph D Patel | President and CEO | M | +24,000 | +$101.04K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Dinesh V Ph D Patel | President and CEO | 522,968 | $67.33M |
| Suneel Gupta | Chief Development Officer | 359,611 | $46.30M |
| Arturo Md Molina | Chief Medical Officer | 99,115 | $12.76M |
| Asif Ali | Chief Financial Officer | 96,670 | $12.45M |
| Harold E Selick | Director | 60,845 | $7.83M |
| Bryan Giraudo | Director | 37,825 | $4.87M |
| Lewis T Williams | Director | 25,825 | $3.32M |
| Sarah A O'Dowd | Director | 7,825 | $1.01M |
| William D. Waddill | Director | 7,825 | $1.01M |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the PTGX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.